ClinicalTrials.gg
CompletedNCT05702450Updated Oct 15, 2024

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

A Phase 1 interventional study of CM310 in Healthy, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.

Read the detailed description

This study includes screening and treatment and follow-up periods.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have the ability to understand the study.
  • Voluntarily participate in the study and sign the ICF.
  • 18 years ≤ age ≤ 65 years, male and female.
  • Willing to take effective measures during the study period.

Exclusion criteria

Exclusion Criteria:

  • Plan to receive any major surgery during the study period.
  • With malignant tumors within 5 years before screening.
  • Positive results of alcohol breath test or urine drug abuse screening during screening period.
  • Any reason that the investigator believes that will prevent the subject from participating in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Group P1

    CM310, Subcutaneous

    Biological: CM310

  • Active comparator
    Group P2

    CM310, Subcutaneous, as the parallel control group

    Biological: CM310

Interventions

  • BiologicalCM310

    CM310 Recombinant Humanized Monoclonal Antibody Injection

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic: the maximum concentration (Cmax)

    Concentration and exposure

    Time frame: up to 57 days

07

Study locations

1 site
  • PKUCare Luzhong Hospital
    Zibo, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jul 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Jan 27, 2023
StartActual
Mar 22, 2023
Primary completionActual
Jul 26, 2023
CompletionActual
Jul 26, 2023
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05702450
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Mar 22, 2023
Primary completion
Jul 26, 2023
Completion
Jul 26, 2023
Last update
Oct 15, 2024

Study contacts

Jie Hou
principal investigator · Peking University Care Luzhong Hospital
Hong Wang
principal investigator · Peking University Care Luzhong Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion